VR Logo

IN8bio Inc. (INAB) download report


Healthcare | Biotechnology & Pharma Research

IN8bio Inc. (INAB) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers.

IPO Date: 30-Jul-2021

Co-Founder, Pres, CEO & Director: Mr. William Ho

Exec. VP, Co-Founder & Chief Scientific Officer: Dr. Lawrence S. Lamb Ph.D.

Listing: NASDAQ: INAB

Country: United States

Headquarters: New York, NY

Website: https://in8bio.com

Key Facts

Market cap: $41.82 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-19.15 Mln

Cash: $32.11 Mln

Total Debt: $2.27 Mln

Insider's Holding: 33.45%

Liquidity: Low

52 Week range: $1.90 - 10.32

Shares outstanding: 18,838,500

Stock Performance

Time Period IN8bio (INAB) S&P BSE Sensex* S&P Small-Cap 600*
YTD-51.03-8.62-18.78
1 month-8.90-4.54-8.00
3 months-35.44-10.19-13.65
1 Year--1.43-17.19
3 Years--10.146.10
5 Years--11.265.87
10 Years--11.829.84
As on 01-Jul-2022 *As on 04-Jul-2022